靶向治疗联合CHOP方案应用于B细胞NHL患者的临床研究

Clinical study of targeted therapy combined with CHOP in the treatment of B-cell NHL patients

目的探讨靶向治疗联合环磷酰胺+吡柔比星+长春新碱+泼尼松(CHOP)方案治疗B细胞非霍奇金淋巴瘤(NHL)的疗效。方法根据治疗方法不同将48例NHL患者分为对照组和观察组,每组24例;对照组患者接受CHOP方案治疗,观察组患者接受利妥昔单抗联合CHOP方案治疗。比较两组患者的治疗效果、不良反应发生情况及生存情况。结果对照组治疗有效率为66.67%,低于观察组患者的91.67%(P﹤0.05)。治疗后,两组患者的卡氏功能状态(KPS)评分均较本组治疗前增高,且观察组患者的KPS评分高于对照组,差异均有统计学意义(P﹤0.05)。两组患者胃肠道反应、骨髓抑制、肺部感染、脱发的发生率比较,差异均无统计学意义(P﹥0.05)。结论靶向治疗联合CHOP方案应用于NHL的治疗效果显著,且安全性较高。

Objective To explore the therapeutic effect of targeted therapy combined with cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP)regimen applied in patients with B-cell non-Hodgkin lymphoma(NHL).Method According to different treatment methods,48 patients with NHL were divided into control group and study group,with 24 cases in each;patients in control group received chemotherapy of CHOP regimen,and patients in study group were administered with rituximab combined with CHOP regimen.The therapeutic effect,incidence of adverse reactions and survival of the two groups of patients were assessed.Result The response rate in control group was 66.67%,which was evidently lower than the 91.67%observed in study group(P<0.05).After treatment,the scores of Karnofsky performance status scale(KPS)of the two groups were increased,and the KPS score of study group was higher than that in control group,the differences were statistically significant(P<0.05).There were no significant differences in regard to the incidence of gastrointestinal reactions,bone marrow suppression,lung infections,and alopecia between the two groups of patients(P>0.05).Conclusion Targeted therapy combined with CHOP regimen is effective in the treatment of NHL with acceptably high safety.